Lyon & Saint-Beauzire, France, June 28th, 2018 – NEURONAX, the biopharmaceutical company dedicated to develop first-in-class disease-modifying drugs to treat patients with neurodegenerative or traumatic neurological disorders, will present its pre-clinical results highlighting the strong potential of its lead product NX210 during the Forum of Neuroscience organized by the Federation of European Neuroscience Societies (FENS) in Berlin Germany, from the 7th to the 11th of June 2018.
The Federation of European Neuroscience Societies (FENS) is the voice of European neuroscience. With 43 neuroscience member societies across 33 European countries, FENS as an organisation represents 24,000 European neuroscientists with a mission to advance European neuroscience education and research.
Forum 2018 – Poster schedule:
ABSTRACT NUMBER: F18-3287
ABSTRACT TITLE: “Thrombospondin repeat derived peptide (NX210) multifunctional activities: neurotrophic, anti-apoptotic and neuroprotective properties“
Session Name: C. DISORDERS OF THE NERVOUS SYSTEM – C.14 Neuroprotection – part II
Date: 10 July 2018
Session Time: 14:00 – 17:30
Poster Board Number: C121